Herpes Simplex Virus 1 (HSV-1) Reactivation in Critically Ill COVID-19 Patients: A Brief Narrative Review.

COVID-19 HSV Herpes simplex ICU Pneumonia Reactivation SARS-CoV-2

Journal

Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 30 05 2022
accepted: 04 07 2022
pubmed: 2 8 2022
medline: 2 8 2022
entrez: 1 8 2022
Statut: ppublish

Résumé

Systemic or pulmonary reactivations of herpes simplex virus 1 (HSV-1) have been reported in critically ill patients with COVID-19, posing a dilemma for clinicians in terms of their diagnostic and clinical relevance. Prevalence of HSV-1 reactivation may be as high as > 40% in this population, but with large heterogeneity across studies, likely reflecting the different samples and/or cut-offs for defining reactivation. There is frequently agreement on the clinical significance of HSV-1 reactivation in the presence of severe manifestations clearly attributable to the virus. However, the clinical implications of HSV-1 reactivations in the absence of manifest signs and symptoms remain controversial. Our review aims at providing immunological background and at reviewing clinical findings on HSV-1 reactivations in critically ill patients with COVID-19.

Identifiants

pubmed: 35913679
doi: 10.1007/s40121-022-00674-0
pii: 10.1007/s40121-022-00674-0
pmc: PMC9340740
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1779-1791

Informations de copyright

© 2022. The Author(s).

Références

Front Immunol. 2020 Oct 14;11:580237
pubmed: 33154753
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Crit Care. 2011 Aug;26(4):432.e1-6
pubmed: 21129912
Biomed Pharmacother. 2020 Dec;132:110859
pubmed: 33120236
Intensive Care Med. 2021 Feb;47(2):180-187
pubmed: 33506379
Physiol Res. 2021 Dec 16;70(S2):S227-S247
pubmed: 34913354
Nutrition. 2013 Jan;29(1):207-12
pubmed: 22951153
J Med Virol. 2004 Jan;72(1):121-5
pubmed: 14635019
Curr Opin Virol. 2011 Dec;1(6):476-86
pubmed: 22323926
Biochimie. 2007 Jun-Jul;89(6-7):878-83
pubmed: 17561326
Ann Rheum Dis. 2016 Oct;75(10):1843-7
pubmed: 27113415
Crit Care. 2020 Aug 28;24(1):530
pubmed: 32859241
Clin Microbiol Infect. 2009 Apr;15(4):358-63
pubmed: 19260875
JAMA Intern Med. 2020 Feb 1;180(2):263-272
pubmed: 31841577
Clin Microbiol Infect. 2020 Nov;26(11):1537-1544
pubmed: 32810610
Rev Med Virol. 2017 Jan;27(1):
pubmed: 27714898
Clin Microbiol Infect. 2022 Apr;28(4):580-587
pubmed: 34454093
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Rev Immunol. 2020 Jul;20(7):397-398
pubmed: 32457522
Lancet Rheumatol. 2020 Jul;2(7):e428-e436
pubmed: 32835246
PLoS One. 2020 Aug 20;15(8):e0237831
pubmed: 32817707
Multidiscip Respir Med. 2022 Mar 01;17(1):815
pubmed: 35340709
PLoS Pathog. 2021 Apr 16;17(4):e1009448
pubmed: 33861802
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276
Microorganisms. 2021 Sep 07;9(9):
pubmed: 34576791
Lancet. 2003 Nov 8;362(9395):1536-41
pubmed: 14615108
Intensive Care Med. 2008 Dec;34(12):2202-9
pubmed: 18679655
Ann Hematol. 2022 Jan;101(1):229-231
pubmed: 33458783
Expert Rev Respir Med. 2022 Apr;16(4):437-446
pubmed: 35341424
J Infect Dis. 2016 Oct 1;214 Suppl 2:S67-74
pubmed: 27625433
Nat Med. 2009 May;15(5):496-7
pubmed: 19424209
Cytokine Growth Factor Rev. 2013 Apr;24(2):91-104
pubmed: 23102645
Endocrinol Diabetes Metab. 2020 Aug 14;4(1):e00176
pubmed: 32904932
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Front Biosci (Landmark Ed). 2021 Sep 30;26(9):405-408
pubmed: 34590454
Ir J Med Sci. 2022 Jun;191(3):1093-1097
pubmed: 34247308
Am J Respir Crit Care Med. 2007 May 1;175(9):935-42
pubmed: 17234903
J Infect. 2019 Feb;78(2):127-133
pubmed: 30267802
Crit Care. 2020 Sep 29;24(1):584
pubmed: 32993740
Infect Dis Now. 2021 Nov;51(8):676-679
pubmed: 34332165
J Virol. 2022 Feb 23;96(4):e0151021
pubmed: 34935440
Cell Rep. 2020 Oct 6;33(1):108234
pubmed: 32979938
PLoS One. 2021 Jul 1;16(7):e0254129
pubmed: 34197543
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Clin Infect Dis. 2021 Jul 1;73(1):e252-e255
pubmed: 32840571
Adv Exp Med Biol. 2015;872:217-33
pubmed: 26215996
Nat Med. 2022 Jan;28(1):201-211
pubmed: 34782790
Nat Genet. 2003 Mar;33(3):388-91
pubmed: 12590259
Front Immunol. 2021 Sep 20;12:742631
pubmed: 34616404
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Gene Rep. 2021 Dec;25:101417
pubmed: 34778602
Nat Immunol. 2022 Feb;23(2):165-176
pubmed: 35105981
Clin Transl Immunology. 2021 Aug 17;10(8):e1327
pubmed: 34429968
Infect Dis Rep. 2021 Dec 10;13(4):1053-1060
pubmed: 34940406
PLoS Pathog. 2015 Jul 08;11(7):e1005028
pubmed: 26153886
Microorganisms. 2022 Feb 04;10(2):
pubmed: 35208817
Br J Dermatol. 2020 Dec;183(6):1145-1147
pubmed: 32790074
J Clin Med. 2021 Feb 03;10(4):
pubmed: 33546093
Cureus. 2021 Sep 16;13(9):e18022
pubmed: 34667693
J Clin Virol. 2013 Sep;58(1):79-83
pubmed: 23731844
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
PLoS One. 2012;7(12):e51340
pubmed: 23236477
Crit Care. 2021 Dec 6;25(1):417
pubmed: 34872611

Auteurs

Daniele Roberto Giacobbe (DR)

Department of Health Sciences (DISSAL), University of Genoa, Via A. Pastore 1, 16132, Genoa, Italy. danieleroberto.giacobbe@unige.it.
Infectious Diseases Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy. danieleroberto.giacobbe@unige.it.

Stefano Di Bella (S)

Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, 34127, Trieste, Italy.

Antonio Lovecchio (A)

Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, 34127, Trieste, Italy.

Lorenzo Ball (L)

Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy.
Anesthesia and Intensive Care, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy.

Andrea De Maria (A)

Department of Health Sciences (DISSAL), University of Genoa, Via A. Pastore 1, 16132, Genoa, Italy.
Infectious Diseases Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy.

Antonio Vena (A)

Department of Health Sciences (DISSAL), University of Genoa, Via A. Pastore 1, 16132, Genoa, Italy.
Infectious Diseases Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy.

Bianca Bruzzone (B)

Hygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy.

Giancarlo Icardi (G)

Department of Health Sciences (DISSAL), University of Genoa, Via A. Pastore 1, 16132, Genoa, Italy.
Hygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy.

Paolo Pelosi (P)

Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy.
Anesthesia and Intensive Care, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy.

Roberto Luzzati (R)

Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, 34127, Trieste, Italy.

Matteo Bassetti (M)

Department of Health Sciences (DISSAL), University of Genoa, Via A. Pastore 1, 16132, Genoa, Italy.
Infectious Diseases Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy.

Classifications MeSH